Key facts
- It has raised $19.7M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Centurium Capital, DaShenLin Pharmaceutical, SDIC Chuangyi, Suzhou Nongfa Innovation Venture Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Genebox
- ·The full record, as it builds
Funding rounds
No funding rounds for Genebox are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genebox
Provider of a consumer genetics testing services intended to help consumers better understand their genetics information. The company offers ancestry analysis, genetic trait evaluation, disease susceptibility assessment, drug response guidance, and personalized wellness plan, thereby enabling users to understand their genetic profile, optimize health decisions, and access tailored preventive care without invasive procedures.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Employees
- 46
- Website
- genebox.cn/
- Ownership
- Privately Held (backing)
Genebox doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genebox shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genebox in its N-PORT filings yet. We sweep new filings monthly.